Increased 20S Proteasome Expression and the Effect of Bortezomib during Cisplatin-Induced Muscle Atrophy

• Published in: Biological & pharmaceutical bulletin Vol. 45; no. 7; pp. 910 - 918
• Main Authors: Sakai, Hiroyasu, Zhou, Yujie, Miyauchi, Yu, Suzuki, Yuta, Ikeno, Yohei, Kon, Risako, Ikarashi, Nobutomo, Chiba, Yoshihiko, Hosoe, Tomoo, Kamei, Junzo
• Format: Journal Article
• Language: English
• Published: Tokyo The Pharmaceutical Society of Japan 01.07.2022; Japan Science and Technology Agency
• Subjects: Atrophy; Bortezomib; Chemotherapy; Cisplatin; Gene expression; muscle atrophy; proteasome; Proteasome inhibitors; Quadriceps muscle; Skeletal muscle; Targeted cancer therapy; Ubiquitin; Ubiquitin-protein ligase
• ISSN: 0918-6158; 1347-5215
• DOI: 10.1248/bpb.b22-00177

Cisplatin is a chemotherapy drug used to treat a variety of cancers. Muscle loss in cancer patients is associated with increased cancer-related mortality. Previously, we suggested that cisplatin administration increases the atrophic gene expressions of ubiquitin E3 ligases, such as atrogin-1 and muscle RING finger-1 (MuRF1), which may lead to muscle atrophy. In this study, C57BL/6J mice were treated with cisplatin (3 mg/kg, intraperitoneally) or saline for 4 consecutive days. Twenty-four hours after the final injection of cisplatin, quadriceps muscles were removed from the mice. The gene expression of Psma and Psmb, which comprise the 20S proteasome, was upregulated by cisplatin administration in the quadriceps muscle of mouse. Systemic administration of cisplatin significantly reduced not only the quadriceps muscle mass but also the diameter of the myofibers. In addition, bortezomib (0.125 mg/kg, intraperitoneally) was administered 30 min before each cisplatin treatment. The co-administration of bortezomib, a proteasome inhibitor, significantly recovered the reductions in the mass of quadriceps and myofiber diameter, although it did not recover the decline in the forelimb and forepaw strength induced by cisplatin. Increased 20S proteasome abundance may play a significant role in the development of cisplatin-induced muscle atrophy. During cisplatin-induced skeletal muscle atrophy, different mechanisms may be involved between loss of muscle mass and strength. In addition, it is suggested that bortezomib has essentially no effect on cisplatin-induced muscle atrophy.